Reference
Jiang J, et al. The very early tumor regression rate and safety of anlotinib combined with sintilimab and chemotherapy for advanced nonsmall cell lung cancer without driver mutations. Journal of Clinical Oncology 39 (Suppl.): e21090, No. 15, 20 May 2021. Available from: URL: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.e21090 [abstract]
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1869, 40 (2021). https://doi.org/10.1007/s40278-021-00905-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-00905-4